90 related articles for article (PubMed ID: 21877752)
41. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma.
Lu SN; Wang JH; Liu SL; Hung CH; Chen CH; Tung HD; Chen TM; Huang WS; Lee CM; Chen CC; Changchien CS
Cancer; 2006 Nov; 107(9):2212-22. PubMed ID: 17019738
[TBL] [Abstract][Full Text] [Related]
42. Secretory/releasing proteome-based identification of plasma biomarkers in HBV-associated hepatocellular carcinoma.
Yang L; Rong W; Xiao T; Zhang Y; Xu B; Liu Y; Wang L; Wu F; Qi J; Zhao X; Wang H; Han N; Guo S; Wu J; Gao Y; Cheng S
Sci China Life Sci; 2013 Jul; 56(7):638-46. PubMed ID: 23749381
[TBL] [Abstract][Full Text] [Related]
43. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples.
Göbel T; Vorderwülbecke S; Hauck K; Fey H; Häussinger D; Erhardt A
World J Gastroenterol; 2006 Dec; 12(47):7604-12. PubMed ID: 17171788
[TBL] [Abstract][Full Text] [Related]
44. Quantitative Proteomics Analysis of Tissue Interstitial Fluid for Identification of Novel Serum Candidate Diagnostic Marker for Hepatocellular Carcinoma.
Sun W; Xing B; Guo L; Liu Z; Mu J; Sun L; Wei H; Zhao X; Qian X; Jiang Y; He F
Sci Rep; 2016 May; 6():26499. PubMed ID: 27216119
[TBL] [Abstract][Full Text] [Related]
45. HCC-DETECT: a combination of nuclear, cytoplasmic, and oncofetal proteins as biomarkers for hepatocellular carcinoma.
Attallah AM; El-Far M; Malak CA; Omran MM; Shiha GE; Farid K; Barakat LA; Albannan MS; Attallah AA; Abdelrazek MA; Elbendary MS; Sabry R; Hamoda GA; Elshemy MM; Ragab AA; Foda BM; Abdallah SO
Tumour Biol; 2015 Sep; 36(10):7667-74. PubMed ID: 25929809
[TBL] [Abstract][Full Text] [Related]
46. [Expression and significance of epidermal growth factor receptor variant type III in hepatocellular carcinoma].
Ou C; Wu FX; Luo Y; Cao J; Zhao YN; Yuan WP; Li Y; Su JJ
Ai Zheng; 2005 Feb; 24(2):166-9. PubMed ID: 15694026
[TBL] [Abstract][Full Text] [Related]
47. Serum protein isoform profiles indicate the progression of hepatitis C virus-induced liver diseases.
Sugimoto K; Shiraki K; Takei Y; Ito M; Nobori T; Suzuki H; Dissanayaka SK; Meno K; Asashima M; Uchida K
Int J Mol Med; 2013 Apr; 31(4):943-50. PubMed ID: 23381678
[TBL] [Abstract][Full Text] [Related]
48. Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation.
Wang L; Sun L; Huang J; Jiang M
Cell Prolif; 2011 Jun; 44(3):291-9. PubMed ID: 21535270
[TBL] [Abstract][Full Text] [Related]
49. In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discovery.
Zhang J; Hao N; Liu W; Lu M; Sun L; Chen N; Wu M; Zhao X; Xing B; Sun W; He F
Br J Cancer; 2017 Nov; 117(11):1676-1684. PubMed ID: 29024941
[TBL] [Abstract][Full Text] [Related]
50. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.
Lin SH; Lee YC; Choueiri MB; Wen S; Mathew P; Ye X; Do KA; Navone NM; Kim J; Tu SM; Yu-Lee LY; Logothetis CJ
Clin Cancer Res; 2008 Jun; 14(12):3729-36. PubMed ID: 18559590
[TBL] [Abstract][Full Text] [Related]
51. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells.
Chen N; Ye XC; Chu K; Navone NM; Sage EH; Yu-Lee LY; Logothetis CJ; Lin SH
Cancer Res; 2007 Jul; 67(14):6544-8. PubMed ID: 17638862
[TBL] [Abstract][Full Text] [Related]
52. PanelComposer: a web-based panel construction tool for multivariate analysis of disease biomarker candidates.
Jeong SK; Na K; Kim KY; Kim H; Paik YK
J Proteome Res; 2012 Dec; 11(12):6277-81. PubMed ID: 23140350
[TBL] [Abstract][Full Text] [Related]
53. Antipyrine clearance in chronic and neoplastic liver diseases: a study of 518 patients.
Grieco A; Castellano R; Matera A; Marcoccia S; Di Rocco P; Ragazzoni E; Vecchio FM; Gasbarrini G
J Gastroenterol Hepatol; 1998 May; 13(5):460-6. PubMed ID: 9641640
[TBL] [Abstract][Full Text] [Related]
54. PRM-MS Quantitative Analysis of Isomeric
Gutierrez Reyes CD; Huang Y; Atashi M; Zhang J; Zhu J; Liu S; Parikh ND; Singal AG; Dai J; Lubman DM; Mechref Y
Metabolites; 2021 Aug; 11(8):. PubMed ID: 34436504
[TBL] [Abstract][Full Text] [Related]
55. The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma.
Caviglia GP; Abate ML; Rolle E; Carucci P; Armandi A; Rosso C; Olivero A; Ribaldone DG; Tandoi F; Saracco GM; Ciancio A; Bugianesi E; Gaia S
Biology (Basel); 2021 Mar; 10(3):. PubMed ID: 33799723
[TBL] [Abstract][Full Text] [Related]
56. Elevation of serum riboflavin carrier protein in hepatocellular carcinoma.
Rao PN; Crippin J; Levine E; Hunt J; Baliga S; Balart L; Anthony L; Mulekar M; Raj MH
Hepatol Res; 2006 Jun; 35(2):83-7. PubMed ID: 16713333
[TBL] [Abstract][Full Text] [Related]
57. Proteomic analysis for developing new biomarkers of hepatocellular carcinoma.
Pleguezuelo M; Lopez-Sanchez LM; Rodriguez-Ariza A; Montero JL; Briceno J; Ciria R; Muntane J; de la Mata M
World J Hepatol; 2010 Mar; 2(3):127-35. PubMed ID: 21160983
[TBL] [Abstract][Full Text] [Related]
58. The transferrin isoforms in chronic hepatitis.
Gruszewska E; Wrona A; Gudowska M; Panasiuk A; Cylwik B; Lipartowska-Klimuk K; Flisiak R; Chrostek L
Clin Biochem; 2017 Dec; 50(18):1131-1135. PubMed ID: 28673788
[TBL] [Abstract][Full Text] [Related]
59. Hepatitis and Cirrhosis.
Br Med J; 1963 Jan; 1(5322):5-6. PubMed ID: 20789588
[No Abstract] [Full Text] [Related]
60. Interstitial Chronic Hepatitis.
Chic Med J Exam; 1882 Oct; 45(4):428. PubMed ID: 37617873
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
